- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05801705
비저위험 폐경 전 여성의 호르몬 수용체 양성 초기 유방암에서 토레미펜, 타목시펜, 아로마타제 억제제와 난소 기능 억제의 효능 및 안전성 비교 평가: 실제 연구
비저위험 폐경 전 여성의 호르몬 수용체 양성 초기 유방암에서 토레미펜, 타목시펜, 아로마타제 억제제 + 난소 억제의 효능 및 안전성 비교 평가: 실제 연구
This study aims to enroll premenopausal patients, with early breast cancer who are non-low-risk and hormone receptor-positive and have undergone prior surgical intervention at the Breast Cancer Center of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. These participants, receiving tamoxifen (TAM), toremifene (TOR), or aromatase inhibitors (AI) as adjuvant endocrine therapy and undergoing ovarian function suppression (OFS) treatment, will be divided into three groups, namely TOR+OFS, TAM+OFS, AI+OFS. The study will compare the efficacy and safety of TOR+OFS to that of TAM+OFS or AI+OFS in premenopausal estrogen receptor-positive breast cancer patients by comparing the 5-year disease-free survival (DFS) and quality of life etc. The objective is to evaluate whether TOR+OFS is non-inferior to TAM+OFS or AI+OFS in this specific patient population.
연구 개요
상태
상세 설명
Selective estrogen receptor modulators (SERM), tamoxifen (TAM) and toremifene (TOR), have been proven to be effective in premenopausal estrogen receptor positive breast cancer patients with similar outcomes. In addition, many large-scale long-term follow-up clinical tials, such as ABCSG XII, SOFT, TEXT, ASTRRA, and ZIPP, have confirmed that premenopausal patients with hormone-receptor-positive breast cancer at intermediate to high risk could benefit from ovarian function suppression (OFS) combined with aromatase inhibitor (AI) or TAM. The Asian Breast Cancer Cooperative Group (ABCCG) also recommends OFS+TAM or OFS+AI for the treatment in this specific patient population. Notably, the therapeutic efficacy and safety profile of OFS in conjunction with TOR have yet to be investigated, nor has its comparative effectiveness with OFS plus TAM or OFS plus AI been established.
This study aims to enroll premenopausal patients, with early breast cancer who are non-low-risk and hormone receptor-positive and have undergone prior surgical intervention at the Breast Cancer Center of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. These participants, receiving tamoxifen (TAM), toremifene (TOR), or aromatase inhibitors (AI) as adjuvant endocrine therapy and undergoing ovarian function suppression (OFS) treatment, will be divided into three groups, namely TOR+OFS, TAM+OFS, AI+OFS. The study will compare the efficacy and safety of TOR+OFS to that of TAM+OFS or AI+OFS in premenopausal estrogen receptor-positive breast cancer patients by comparing the 5-year disease-free survival (DFS) and quality of life etc. The objective is to evaluate whether TOR+OFS is non-inferior to TAM+OFS or AI+OFS in this specific patient population.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510120
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
- Female, age ≥ 18
- Premenopausal patients with early hormone receptor-positive breast cancer at intermediate to high risk (Low risk is defined as having the following 6 items at the same time: lesion size (pT) in the specimen <= 2cm; histological grade 1; no vessel carcinoma embolus; ER and/or PR positive; HER2 gene without overexpression or amplification; age >=35 years old)
- Completed radical surgery for breast cancer
- Undergoing postoperative endocrine therapy (toremifene, tamoxifen, aromatase inhibitorI) at least five years at Sun Yat-sen Memorial Hospital of Sun Yat-sen University since 2010
- Undergoing ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)
설명
Inclusion Criteria:
- Female, aged 18-60
- Premenopausal patients with early hormone receptor-positive breast cancer at intermediate to high risk (Low risk is defined as having the following 6 items at the same time: lesion size (pT) in the specimen <= 2cm; histological grade 1; no vessel carcinoma embolus; ER and/or PR positive; HER2 gene without overexpression or amplification; age >=35 years old)
- Completed radical surgery for breast cancer
- Undergoing postoperative endocrine therapy (toremifene, tamoxifen, aromatase inhibitorI) at least five years at Sun Yat-sen Memorial Hospital of Sun Yat-sen University since 2010
- Undergoing ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)
Exclusion Criteria:
- Imaging or pathology suggestive of metastatic breast cancer (chest wall, lung, bone, liver, brain)
- Patients with a second primary tumor
- Hepatic insufficiency at baseline
- Known history of psychotropic substance abuse or drug abuse;
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: CROSS_SECTIONAL
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
OFS+AI
patients undergoing ovarian function suppression (OFS) combined with aromatase inhibitor (AI) |
Aromatase inhibitor includes Arimidex, Aromasin, Femara. Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin |
|
OFS+TAM
patients undergoing ovarian function suppression (OFS) combined with tamoxifen (TAM) |
Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin tamoxifen,10mg, bid |
|
OFS+TOR
patients undergoing ovarian function suppression (OFS) combined with torimifene (TOR) |
Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin toremifene, 60 mg, qd |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
disease free survival
기간: 5 years
|
The time from the beginning of treatment to the recurrence of the disease or death from any cause or the end of the visit |
5 years
|
|
The score of life quality questionnaire assessed by SPF 36
기간: 1 month
|
The score of SPF 36 |
1 month
|
|
The score of life quality questionnaire assessed by EQ-5D-5L
기간: 1 month
|
The score of EQ-5D-5L |
1 month
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The incidence of adverse events
기간: 5 years
|
Incidence of adverse outcome events (such as musculoskeletal symptoms,osteoporosis, fragile, bone mineral density loss, hepatic insufficiency, dyslipidemia, endometrial hyperplasia, uterine fibroids, ovarian cyst, adenomyosis, hot flashes, night sweats etc.) |
5 years
|
공동 작업자 및 조사자
수사관
- 연구 의자: Chang Gong, docto, Sun Yat-sen Memorial Hospital of Sun Yat-sen Univeristy
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 약물의 생리적 효과
- 약리작용의 분자 메커니즘
- 호르몬
- 호르몬, 호르몬 대체제, 호르몬 길항제
- 효소 억제제
- 스테로이드 합성 억제제
- 호르몬 길항제
- 에스트로겐 길항제
- 뇌하수체 호르몬 방출 호르몬
- 시상 하부 호르몬
- 펩티드 호르몬
- 신경 펩티드
- 펩타이드
- 아미노산, 펩티드 및 단백질
- 올리고 펩티드
- 신경 조직 단백질
- 단백질
- 유기 화학 물질
- 수술 절차, 수술
- 약리학 적 행동
- 화학 작용 및 용도
- 탄화수소
- 탄화수소, 순환
- 탄화수소, 방향족
- 벤젠 유도체
- 비뇨 생식기 외과 절차
- 스틸 벤스
- 벤질 리덴 화합물
- 부인과 수술 절차
- 내분비 수술 절차
- 거세
- 타목시펜
- 아로마타제 억제제
- Toremifene
- 성선 자극 호르 핀-방출 호르몬
- 난소절제술
기타 연구 ID 번호
- SYSKY-2022-445-02
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .